Erratum: Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies (BMJ (Online) (2014) 348 (g1888) DOI:10.1136/bmj.g1888);Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Taylor, David ^a,b   Sparshatt, Anna ^b   Varma, Seema ^b   Olofinjana, Olubanke ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; CHOLELITHIASIS; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; INSOMNIA; JAUNDICE; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897133580     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g2496     Document Type: Erratum

References (65)

1. European Medicines Agency. Valdoxan (agomelatine). 2012. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/ human-med-001123.jsp&mid=WC0b01ac058001d124.
2. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011;12:574-87.
3. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011;23:1-12.
4. Medawar C, Hardon A, Herxheimer A. Depressing research. Lancet 2004;363:2087.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
6. Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. (Pubitemid 9136500)
9. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman SD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
10. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Multiple comparisons within a study. In: Introduction to meta-analysis. Wiley-Blackwell, 2009:239-42.
11. Trowman R, Dumville JC, Torgerson DJ, Cranny G. The impact of trial baseline imbalances should be considered in systematic reviews: a methodological case study. J Clin Epidemiol 2007;60:1229-33. (Pubitemid 350061144)
12. Review Manager (RevMan) [Computer program]. Version 5.0. Nordic Cochrane Centre, Cochrane Collaboration, 2008.
13. StataCorp. Stata statistical software: release 11. StataCorp LP, 2009.
14. Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:1128-37.
15. Kasper S, Hajak G. The efficacy of agomelatine in previously-treated depressed patients. Int J Psychiatry Clin Pract 2010;14(suppl 1):26-7.
16. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-80. (Pubitemid 39141943)
17. Vahia V, Yadav A. Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with major depressive disorder. A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg). CL3-20098-074. 2011. [Data from European Medicines Authority.]
18. Novartis Pharmaceuticals Corporation. An 8-week, multicenter, randomized, double-blind, placebo-and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine 25 or 50mg given once daily in the treatment of Major Depressive Disorder (MDD). Study CAGO178A2303. Novartis, 2008. www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult= 2659.
19. Servier. Report including additional analyses: efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks versus fluoxetine (20mg) in in- or out-patients with Major Depressive Disorder. A randomised double-blind, placebo controlled parallel-group study. 18 week optional treatment period. CL3-20098-022. Vol 1/36. 2007. [Data from European Medicines Authority.]
20. Servier. Efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks versus paroxetine, in patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled - parallel groups study, 18-weeks extension period. CL3-20098-023. Vol 1/34. 2004. [Data from European Medicines Authority.]
21. Servier. Efficacy and safety of agomelatine given orally once a day for 6 weeks in patients with Major Depressive Disorder. Confirmation of the efficacy of the agomelatine 25mg dosage and study of the efficacy of agomelatine 50mg dosage. A randomised, double-blind, placebo-controlled, versus fluoxetine, parallel groups study. 18-week continuation period. CL3-20098-024. Vol 1/53. 2004. [Data from European Medicines Authority.]
22. Servier. Efficacy and safety of agomelatine (25mg) given orally once a day for 6 weeks in elderly patients with Major Depressive Disorder. A randomised, double-blind, placebo-controlled, parallel-group study with a 18-week extension period. CL3-20098-026. Vol 1/28. 2004. [Data from European Medicines Authority.]
23. Servier Laboratories. Study CL3-048 - Agomelatine (Servier Data on File). 2008. [Unpublished results supplied by manufacturer.]
24. Servier Laboratories. Study CL3-052 - Agomelatine (Servier Data on File). 2013. [Unpublished results supplied by manufacturer.]
25. Servier Laboratories. Study CL3-063 - Agomelatine (Servier Data on File). 2009. [Unpublished results supplied by manufacturer.]
26. Servier Laboratories. Study CL3-070 - Agomelatine (Servier Data on File). 2009. [Unpublished results supplied by manufacturer.]
27. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010;25:305-14.
28. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Motejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-20.
29. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100. (Pubitemid 43145814)
30. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32. (Pubitemid 350247502)
31. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47.
32. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73. (Pubitemid 47517525)
33. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011;26:252-62.
34. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26.
35. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-44.
36. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33.
37. Kennedy SH, Avedisova A. Efficacy and safety of 3 agomelatine dose regimens (10, 25, 25-50mg) versus placebo in out-patients suffering from moderate to severe major depressive disorder. Abstract presented at 21st European Congress of Psychiatry, Nice, France, 6-9 April 2013.
38. Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V, et al. The efficacy of agomelatine in elderly patients with recurrent Major Depressive Disorder: a placebo-controlled study. J Clin Psychiatry 2013;74:587-94.
39. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32. (Pubitemid 350247502)
40. National Institute for Clinical Excellence. Depression: the treatment and management of depression in adults (update). CG90. NICE, 2009. www.nice.org.uk/.
41. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Dis 2009;118:1-8.
42. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Silva MA. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol 2013;28:12-9.
43. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87.
44. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
45. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 2007;190:287-92. (Pubitemid 46580676)
46. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012;200:97-106.
47. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:f2865.
48. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
49. National Institute for Health and Clinical Excellence. Depression with a chronic physical health problem. Clinical Guidance 91. 2009. www.nice.org.uk/CG91.
50. Taylor D, Paton C, Kapur S. Maudsley prescribing guidelines in psychiatry. 11th ed. Wiley-Blackwell, 2012.
51. Sparshatt A, McAllister Williams RH, Baldwin DS, Haddad PM, Bazire S, Weston E, et al. A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatr Scand 2013;128:203-11.
52. Sevier Laboratories. Summary of Product Characteristics. Valdoxan. Sevier, 2013. www.medicines.org.uk/emc/medicine/21830/SPC/Valdoxan/.
53. Gahr M, Freudenmann RW, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20.
54. Medicines and Healthcare Products Regulatory Agency. Yellow card: drug analysis print. Drug name: agomelatine. 2013. www.mhra.gov.uk/home/groups/ public/documents/sentineldocuments/dap-1382088923328.pdf.
55. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-66.
56. Corruble E, de Bodinat C, Belaïdi C, Goodwin GM; Agomelatine Study Group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 2013;16:2219-34.
57. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011;26:537-42.
58. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012;79:1862-5.
59. Hung CC, Lin CH, Lan TH, Chan CH. The association of selective serotonin reuptake inhibitors use and stroke in geriatric population. Am J Geriatr Psychiatry 2013;21:811-5.
60. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.
61. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011;12:CD006528.
62. Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. J Affect Disord 2006;95:129-33. (Pubitemid 46107026)
63. Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kapser S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 2013;18:163-70.
64. Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012;73:1002-8.
65. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011;34:709-31.